2-甲基-7-硝基-2H-1,4-苯并恶嗪-3(4H)-酮 | 85160-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 2-甲基-7-硝基-2H-1,4-苯并恶嗪-3(4H)-酮
• 中文别名: 2-甲基-7-硝基-2,4-二氢-1,4-苯并恶嗪-3-酮
• 英文名称: 3,4-dihydro-2-methyl-7-nitro-3-oxo-2H-1,4-benzoxazine
• 英文别名: (+/-)-2-methyl-7-nitro-2H-1,4-benzoxazin-3(4H)-one；2-methyl-7-nitro-4H-benzo[1,4]oxazin-3-one；2-methyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one；2-methyl-7-nitro-2-hydro-1,4-benzomorpholin-3-(4-hydro)-one；2-methyl-7-nitro-3,4-dihydro-2H-1,4-benzoxazin-3-one；2-methyl-7-nitro-2,4-dihydro-1,4-benzoxazin-3-one；7-nitro-2-methyl-1,4-benzoxazin-3-one；2-Methyl-7-nitro-2H-1,4-benzoxazin-3(4H)-one；2-methyl-7-nitro-4H-1,4-benzoxazin-3-one
• CAS: 85160-82-3
• 化学式: C₉H₈N₂O₄
• mdl: MFCD10040175
• 分子量: 208.174
• InChiKey: KBLXGQKTRWROCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Methyl-7-nitro-2,4-dihydro-1,4-benzoxazin-3-one
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Methyl-7-nitro-2,4-dihydro-1,4-benzoxazin-3-one
Ingredient name:
CAS number: 85160-82-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8N2O4
Molecular weight: 208.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-7-硝基-2H-1,4-苯并恶嗪-3(4H)-酮 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 以94%的产率得到2-甲基-7-硝基-3,4-二氢-2H-1,4-苯并恶嗪
  参考文献：
  名称：

  Novel Series of Potent, Nonsteroidal, Selective Androgen Receptor Modulators Based on 7H-[1,4]Oxazino[3,2-g]quinolin-7-ones

  摘要：

  Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.

  DOI：

  10.1021/jm061329j
• 作为产物：
  描述：

  2-溴丙酸甲酯 、 2-氨基-5-硝基苯酚 在 potassium fluoride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.25h， 生成 2-甲基-7-硝基-2H-1,4-苯并恶嗪-3(4H)-酮
  参考文献：
  名称：

  [EN] INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
  [FR] INHIBITEURS DE L'INTERACTION ENTRE MDM2 ET P53

  摘要：

  本发明提供了公式(I)的化合物，它们用作p53-MDM2相互作用的抑制剂，以及包含所述化合物的药物组合物：其中n、s、t、R1、R2、R3、R4、R5、X、Y、Q、Z、G、E和D具有定义的含义。

  公开号：

  WO2009037343A1

文献信息

• Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities
  作者：Li Liu、Yongxia Zhu、Zhihao Liu、Tinghong Ye、Weiqiong Zuo、Cuiting Peng、Kunjie Xiao、Ningyu Wang、Luoting Yu

  DOI：10.1007/s11030-016-9707-6

  日期：2017.2

  in particular BRD4, has been reported to play important roles in cancer, inflammation, obesity, cardiovascular disease, and neurological disorders. In this paper, a series of benzomorpholinone derivatives were synthesized and biologically evaluated as BETs inhibitors. Detailed structure–activity relationship studies led to the discovery of several new potent compounds, of which 15h and 15i displayed

  溴结构域和末端外蛋白（BETs），特别是BRD4，据报道在癌症，炎症，肥胖，心血管疾病和神经系统疾病中起重要作用。本文合成了一系列苯并吗啉酮衍生物，并作为BETs抑制剂进行了生物学评估。详细的结构-活性关系的研究导致了几个新的有效化合物的发现，其中15H和15I显示\（\文本IC} _ 50} \）的2.8和4.5的值\（\ upmu} \文本M } \）分别针对BRD4（D1），并在低微摩尔浓度下对四种血液系统恶性肿瘤细胞系表现出良好的抗增殖活性，其中包括MV4-11，OCI-LY10，Pfeifer和Su-DHL-6细胞。将来，就其功效和类药物特性而言，该化学型可以进一步优化。
• Androgen receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals, Inc.

  公开号：US06462038B1

  公开（公告）日：2002-10-08

  Compounds, pharmaceutical compositions, and methods for modulating processes mediated by steroid receptors. In particular, preparation and methods of use of non-steroidal compounds and compositions that are agonists, partial agonists, and antagonists for the androgen receptor (AR) are described. Further, described are the methods of making and use of critical intermediates including a stereoselective synthetic route to intermediates for the AR modulators.

  化合物、药物组合物和调节类固醇受体介导过程的方法。具体描述了非类固醇化合物和组合物的制备和使用方法，这些化合物和组合物是雄激素受体（AR）的激动剂、部分激动剂和拮抗剂。此外，还描述了制备和使用关键中间体的方法，包括用于AR调节剂的立体选择性合成路线。
• 苯并吗啉酮衍生物及其制备方法和用途
  申请人：四川大学

  公开号：CN107459494B

  公开（公告）日：2021-02-05

  本发明属于化学医药领域，具体涉及苯并吗啉酮衍生物及其制备方法和用途。本发明提供了一种苯并吗啉酮衍生物，其结构如式Ⅰ所示。本发明还提供了上述苯并吗啉酮衍生物的制备方法和用途。本发明提供的苯并吗啉酮衍生物，结构新颖，对BET靶点具有良好的选择性抑制作用，对多种肿瘤细胞都有不同程度的细胞毒，是一类新型的BET小分子抑制剂，本发明化合物具有开发抗肿瘤药物的潜力。
• 嘧啶并吗啉衍生物及其制备方法和用途
  申请人：四川大学

  公开号：CN108164548B

  公开（公告）日：2020-09-08

  本发明属于化学医药领域，具体涉及抗甲状腺髓样癌、抗急性白血病和抗炎小分子化合物及其制备方法和用途。本发明要解决的技术问题是目前临床上针对甲状腺髓样癌的上市药物选择性较差、且易产生耐药和毒副作用的缺点。本发明解决上述技术问题的方案是提供了一种嘧啶并吗啉衍生物，该衍生物主要是在嘧啶6位有取代，其结构如式Ⅰ所示。本发明提供的化合物具有抗甲状腺髓样癌活性高且毒副作用低，并能克服临床耐药的优点，在针对甲状腺髓样癌的药物开发上具有很大的价值。
• [DE] NEUE MIT BICYCLEN SUBSTITUIERTE OXAZOLIDINONE<br/>[EN] NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES<br/>[FR] NOUVELLES OXAZOLIDINONES A SUBSTITUTION BICYCLENE
  申请人：BAYER AKTIENGESELLSCHAFT

  公开号：WO1999037641A1

  公开（公告）日：1999-07-29

  (DE) Die vorliegende Erfindung betrifft neue, mit Bicyclen substituierte Oxazolidinone, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel, insbesondere als antibakterielle Arzneimittel.(EN) The present invention relates to novel bicyclene-substituted oxazolidinones, to a method for the production and to the use thereof as medicaments, especially as antibacterial medicaments.(FR) L'invention concerne de nouvelles oxazolidinones à substitution bicyclène, leurs procédés de préparation et leur utilisation comme médicaments, notamment comme médicaments antibactériens.

  （DE）本发明涉及新型的含有双环替代基的噁唑烷酮化合物，其制备方法以及作为药物的使用，特别是作为抗菌药物。（EN）本发明涉及新型的含有双环替代基的噁唑烷酮化合物，其制备方法以及作为药物的使用，特别是作为抗菌药物。（FR）本发明涉及新型的含有双环替代基的噁唑烷酮化合物，其制备方法以及作为药物的使用，特别是作为抗菌药物。